T‐cell antibody induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
T‐cell antibody induction showed no clear difference in acute rejection grade II or higher compared with no antibody induction (moderate certainty).
T‐cell antibody induction showed no clear difference in infection compared with no antibody induction (moderate certainty).
T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in mortality compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in acute rejection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in infection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in acute rejection grade II or higher compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in infection compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).